As inflammation and oxidative stress are thought to be important causes of liver cancer and liver disease ([@bib12]; [@bib9]), antioxidants might have a beneficial effect. Several previous observational studies have indicated that higher serum levels of serum *α*-tocopherol, *β*-carotene, and retinol are associated with a reduced risk of liver cancer or disease ([@bib11]; [@bib20]; [@bib18]; [@bib19]; [@bib3]; [@bib5]; [@bib21]). Other studies, including trials, have reported beneficial effects of vitamin E supplementation on these outcomes ([@bib15]; [@bib17]; [@bib1]; [@bib22]) including recent data on non-diabetic persons with NASH (non-alcoholic steatohepatitis) in the PIVENS (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis) trial ([@bib14]) that has served as the basis of recent AASLD clinical recommendations ([@bib2]). Concordant results were recently found for the use of vitamin E supplements and liver cancer in an observational cohort in Shanghai, China ([@bib22]). However, the long-term effect of vitamin E supplementation on liver disease is unclear ([@bib8]; [@bib10]; [@bib1]).

Materials and methods
=====================

We evaluated the effects of *α*-tocopherol and *β*-carotene supplementation on liver cancer incidence and chronic liver disease (CLD) mortality in the Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) study, a large randomised placebo-controlled trial of 29 105 Finnish male smokers, aged 50--69 at baseline, without self-reported cirrhosis who received 50 mg day^-1^ DL-*α*-tocopheryl acetate, 20 mg day^-1^ *β*-carotene, both, or placebo from enrolment in 1985--1988 until April 30, 1993 ([@bib16]). Follow-up was through cancer diagnosis, death, or until 31 December 2009. Although designed to examine lung cancer, ATBC provided a unique opportunity to evaluate the long-term effects of *α*-tocopherol and *β*-carotene supplementation on liver cancer incidence and CLD mortality.

Incident liver cancer cases (*n*=208; ICD-9=155, and ICD-10=C22) and mortality from CLD (*n*=237; ICD-9=571, and ICD-10=K70, K73, or K74) were identified through the Finnish Cancer Registry ([@bib7]) and Finnish Register of Causes of Death, respectively. All statistical analyses were based on intention-to-treat. Kaplan--Meier survival curves were plotted for the four intervention groups on the scale of time since randomisation. The effect of intervention was estimated by Cox proportional hazards regression with age as the time scale and allowing for left truncation.

We examined the results in the pre-specified baseline subgroups, defined by age, alcohol use, BMI, cigarettes per day, baseline serum *α*-tocopherol, serum *β*-carotene, or serum total cholesterol. These analyses were designed primarily to assess consistency of the overall results, rather than discover subsets where treatment effects might be present. We also assessed associations among a subset of participants with measured hepatitis B (HBV) and C (HCV) viral status, and fasting glucose and insulin. Diabetes status was defined as: without diabetes (blood glucose \<100 mg dl^−1^ and no history of diabetes), prediabetes (blood glucose between 100 and \<126 mg dl^−1^ and no history of diabetes), and diabetes (blood glucose ⩾126 mg dl^−1^ or self-reported history of diabetes). This subset analysis was motivated by findings in the literature suggesting a benefit from *α*-tocopherol in the absence of diabetes. We used a *P*-value of 0.05 for statistical significance and all the tests were two-sided. Additional details on the methods can be found in the supplement.

Results
=======

The ATBC trial was randomised, and the baseline characteristics were similar across each intervention arm ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). During follow-up, 208 incident liver cancer cases and 237 deaths from CLD occurred. We observed no effect of supplemental *α*-tocopherol, *β*-carotene, or both, relative to placebo, on liver cancer incidence (hazard ratio (HR) for *α*-tocopherol, 1.18; 95% confidence interval (CI), 0.79--1.75; HR for *β*-carotene, 1.26; 95% CI, 0.85--1.87; HR for both, 1.21, 95% CI, 0.81--1.80) or CLD mortality (HR for *α*-tocopherol, 0.97; 95% CI, 0.68--1.40; HR for *β*-carotene, 1.06; 95% CI, 0.74--1.51; HR for both, 1.01, 95% CI, 0.70--1.45). Similar results were found during the intervention and post-intervention period ([Table 1](#tbl1){ref-type="table"}; [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}).

Results were similar across the examined subgroups previously mentioned in the methods section (data not shown) and after excluding the few (0.8% for HBsAg) HBV or (1.6% for anti-HCV) HCV-positive cases (data not shown), although they appeared to vary by diabetes status. Among a subset of participants with information on fasting insulin and glucose, an effect of *α*-tocopherol *vs*. no *α*-tocopherol on CLD was observed among men without diabetes (odds ratio (OR), 0.53; 95% CI, 0.33--0.86), but not among men with prediabetes (OR, 1.53; 95% CI, 0.94--2.47) or diabetes (OR, 1.27; 95% CI, 0.51--3.14; *P* interaction=0.009) ([Table 1](#tbl1){ref-type="table"}). A suggestive protective effect was observed in *β*-carotene *vs*. no *β*-carotene on CLD in men with diabetes (OR, 0.46; 95% CI, 0.18--1.17) but not in men without diabetes or with prediabetes (*P*interaction=0.09). No differences by diabetes status were observed for liver cancer (all *P*interactions \>0.20) ([Table 1](#tbl1){ref-type="table"}).

Discussion
==========

Overall, our study provides no evidence for a benefit of supplementation with *α*-tocopherol and/or *β*-carotene supplementation on liver cancer incidence or CLD mortality in middle-aged participants. Indeed, the observed HRs exceeded 1.00 for most comparisons. It is possible that intervention benefits were not detected because the numbers of incident liver cancers and deaths from CLD were limited. The lower confidence limits in the analyses do suggest that if there are risk reductions from these interventions that we could not detect because of limited sample size, they would be modest (21% and 32% lower from supplemental *α*-tocopherol for liver cancer and CLD mortality, respectively, and 15% and 26% lower from supplemental *β*-carotene).We also note that our subgroup analyses (data not shown) indicated consistent null findings across a range of other exposures.

An exception to this pattern was evidence for a benefit of *α*-tocopherol on CLD mortality in men without diabetes. It is not clear why the effects may differ by diabetes, and chance is a possible explanation. Although these results are consistent with recent findings from the PIVENS trial ([@bib14]), which observed that daily supplementation with 800 IU of *α*-tocopherol had a beneficial effect on NASH progression over 96 weeks in patients lacking diabetes, there are substantial differences between the design of PIVENS and ATBC. A lower dose of *α*-tocopherol was given in our study (50 IU) and our supplementation period (5--8 years) and follow-up (24 years) were substantially longer. Also, the PIVENS trial enrolled participants with pre-existing NASH, whereas the ATBC study enrolled participants from the general population, most of who probably lacked NASH. Several other smaller trials have reported a beneficial effect of vitamin E supplementation on treating patients with NASH ([@bib15]; [@bib17]; [@bib1]) and for other liver diseases ([@bib1]). These studies, like the PIVENS trial, enrolled a specific population, that is, patients with pre-existing liver disease and supplemented with higher doses of vitamin E, which contrast notably with the general Finnish population that made up the ATBC study participants and the lower dose of *α*-tocopherol.

Our analyses treated deaths from other causes as independent censoring at the time of the death. Unlike analyses of cumulative incidence over a long time interval ([@bib4]), these analyses would not be distorted by differences in the amount of competing mortality among the intervention groups. In any case, mortality rates from other causes were similar across the treatment groups, both overall and in participants with and without diabetes.

Other data on micronutrient supplementation and liver cancer are sparse. Whereas a Chinese observational cohort recently reported an inverse association of both vitamin E supplement use and dietary vitamin E intake with liver cancer ([@bib22]), no effect was observed for 'factor D\' (*β*-carotene (15 mg), *α*-tocopherol (30 mg), and selenium (50 *μ*g)) on liver cancer mortality, relative to placebo in the Linxian General Population Nutrition Intervention Trial ([@bib13]).

In apparent contrast with our results for *α*-tocopherol and *β*-carotene supplementation, micronutrient status, as assessed by serum levels, has been associated with lower risk of liver cancer in several prospective cohort studies ([@bib6]; [@bib20]; [@bib5]; [@bib21]), including in the current one (companion paper). Within ATBC, we observed that higher baseline levels of serum *β*-carotene and retinol were associated with a reduced risk of incident liver cancer and CLD mortality, whereas higher baseline *α*-tocopherol levels were associated with a lower risk of CLD mortality but not incident liver cancer. Such contrasting results do not necessarily conflict. Serum micronutrient status reflects on the long-term dietary intake and metabolism. Micronutrient supplementation during middle age may miss the important window of liver disease and liver cancer development. Alternatively, serum micronutrient levels may serve as a proxy for another aspect of diet or lifestyle, and may not actually have a direct role in the development of liver disease and liver cancer.

Our study has several strengths, including large size, randomised design, evaluation of *α*-tocopherol or *β*-carotene supplementation separately, long-term follow-up over 24 years, minimal loss to follow-up, and information on major liver cancer risk factors including HBV, HCV, alcohol, and diabetes. Limitations included the modest numbers of liver cancer cases and deaths from CLD; the primary purpose of the ATBC Study was to evaluate whether these supplements could reduce the lung cancer risk. We lacked information about fibrosis and NASH at baseline and also about incident liver disease. However, ATBC excluded subjects with a baseline history of cirrhosis or alcoholism. As ATBC was conducted among Finnish male smokers, our results may not apply to other populations. Finally, liver cancer incidence and mortality from CLD were not primary end points of ATBC, and we examined numerous subgroups. Thus findings in subgroups may well be due to chance.

In summary, in a large randomised trial, *α*-tocopherol and *β*-carotene supplementation had no overall effect on the incidence of liver cancer or on mortality from CLD over the course of 24 years of follow-up either during the intervention period or in the post-intervention follow-up period. Effects were noted in certain subgroups of baseline diabetes status, but these findings were based on a small number of cases. Future studies are needed to examine these subgroup findings, as they may be due to chance.
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Click here for additional data file.

![**Kaplan--Meier estimates of the probability of no diagnosis of liver cancer among participants randomised to *α*-tocopherol (AT), *β*-carotene (BC), combination or placebo arms.**](bjc2014514f1){#fig1}

![**Kaplan--Meier estimates of the probability of survival from mortality from chronic liver disease among participants randomised to *α*-tocopherol (AT), *β*-carotene (BC), combination or placebo arms.**](bjc2014514f2){#fig2}

###### Effect of *α*-tocopherol and *β*-carotene on incident liver cancer and chronic liver disease mortality, ATBC Study

                                                     **Placebo**   *α***-Tocopherol**   ***β*-Carotene**    ***α*-Tocopherol+*β*-carotene**   **No** *α***-tocopherol**   *α***-Tocopherol**   **No** *β***-carotene**   *β***-Carotene**
  ------------------------------------------------- ------------- -------------------- ------------------- --------------------------------- --------------------------- -------------------- ------------------------- -------------------
  **Incident liver cancer**                                                                                                                                                                                             
  **All participants**[a](#t1-fn1){ref-type="fn"}                                                                                                                                                                                 
   Cases/all                                           45/7282          53/7280              56/7274                    54/7269                      101/14 556               107/14 549              98/14 562             110/14 543
   Entire period                                        1.00       1.18 (0.79--1.75)    1.26 (0.85--1.87)          1.21 (0.81--1.80)                    1.00              1.06 (0.81--1.39)             1.00             1.13 (0.86--1.49)
   Cases/all                                           10/7282           9/7280              8/7274                     9/7269                        18/14 556               18/14 549               19/14 562              17/14 543
   Trial period                                         1.00       0.88 (0.36--2.17)    0.76 (0.30--1.93)          0.88 (0.36--2.15)                    1.00              1.00 (0.52--1.92)             1.00             0.87 (0.45--1.68)
   Cases/all                                           35/6433          44/6412              48/6360                    45/6339                       83/12 793               89/12 751               79/12 845              93/12 699
   Post-trial period                                    1.00       1.25 (0.80--1.95)    1.40 (0.90--2.16)          1.29 (0.83--2.01)                    1.00              1.07 (0.79--1.44)             1.00             1.19 (0.88--1.61)
  **Subset**[b](#t1-fn2){ref-type="fn"}                                                                                                                                                                                           
   Cases/controls                                       10/98            14/107               10/83                      11/78                         20/181                   25/185                 24/205                 21/161
   Without diabetes                                     1.00       1.38 (0.58--3.32)    1.14 (0.44--2.93)          1.46 (0.58--3.69)                    1.00              1.33 (0.70--2.52)             1.00             1.08 (0.57--2.03)
   Cases/controls                                       18/67            18/79                19/75                      14/72                         37/142                   32/151                 36/146                 33/147
   Prediabetes                                          1.00       0.91 (0.43--1.93)    0.99 (0.47--2.07)          0.70 (0.32--1.55)                    1.00              0.81 (0.48--1.39)             1.00             0.89 (0.52--1.52)
   Cases/controls                                       6/16              5/11                7/23                       12/12                          13/39                   17/23                   11/27                  19/35
   With diabetes                                        1.00       0.94 (0.21--4.13)    0.92 (0.25--3.45)         3.08 (0.84--11.29)                    1.00              2.03 (0.81--5.09)             1.00             1.70 (0.65--4.45)
  **Chronic liver disease mortality**                                                                                                                                                                                   
  **All participants**[a](#t1-fn1){ref-type="fn"}                                                                                                                                                                                 
   Cases/all                                           59/7282          57/7280              62/7274                    59/7269                      121/14 556               116/14 549             116/14 562             121/14 543
                                                        1.00       0.97 (0.68--1.40)    1.06 (0.74--1.51)          1.01 (0.70--1.45)                    1.00              0.96 (0.75--1.24)             1.00             1.05 (0.82--1.36)
   Cases/all                                           14/7282          18/7280              16/7274                    20/7269                       30/14 556               38/14 549               32/14 562              36/14 543
   Trial period                                         1.00       1.27 (0.63--2.56)    1.12 (0.55--2.30)          1.40 (0.71--2.78)                    1.00              1.26 (0.78--2.03)             1.00             1.11 (0.69--1.79)
   Cases/all                                           45/6433          39/6412              46/6360                    39/6339                       91/12 793               78/12 751               84/12 845              85/12 699
   Post-trial period                                    1.00       0.87 (0.57--1.33)    1.04 (0.69--1.56)          0.88 (0.57--1.35)                    1.00              0.86 (0.63--1.16)             1.00             1.09 (0.81--1.47)
  **Subset**[b](#t1-fn2){ref-type="fn"}                                                                                                                                                                                           
   Cases/controls                                       31/98            14/107               27/83                      19/78                         58/181                   33/185                 45/205                 46/161
   Without diabetes                                     1.00       0.40 (0.20--0.80)    1.01 (0.55--1.83)          0.71 (0.37--1.36)                    1.00              0.53 (0.33--0.86)             1.00             1.26 (0.79--2.00)
   Cases/controls                                       14/67            27/79                21/75                      30/72                         35/142                   57/151                 41/146                 51/147
   Prediabetes                                          1.00       1.51 (0.72--3.13)    1.23 (0.57--2.63)          1.96 (0.95--4.04)                    1.00              1.53 (0.94--2.47)             1.00             1.23 (0.77--1.98)
   Cases / controls                                     10/16             9/11                8/23                       4/12                           18/39                   13/23                   19/27                  12/35
   With diabetes                                        1.00       1.59 (0.46--5.48)    0.60 (0.18--1.96)          0.49 (0.11--2.09)                    1.00              1.27 (0.51--3.14)             1.00             0.46 (0.18--1.17)

Presented as HRs and 95% CIs.

Presented as ORs and 95% CIs.
